Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older

Summary

The purpose of this Phase IIb study is to evaluate the efficacy of the RSV vaccine candidate for the prevention of lower respiratory tract disease (LRTD) due to RSV. The study will enroll approximately 4500 adults aged 60 years and older in a 1:1 ratio to receive a single intra-muscular (IM) administration of either a pre-determined dose of the RSV vaccine candidate or placebo.

Timeline

Start

2024-04-02

Primary completion

2025-03-11

Completion

2025-03-11

Drugs

Indications